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BRIEF REPORT: CLINICAL SCIENCE
HIV-1 gp120 T-Cell Responses Correspond to Infection
Outcomes in the Global iPrEx Chemoprophylaxis Trial
Peter J. Kuebler, PharmD,* Brian I. Shaw, BS,* Kaitlyn S. Leadabrand, BS,* Megha L. Mehrotra, MPH,†
Robert M. Grant, MD,†‡ Esper G. Kallás, MD, PhD,§ and Douglas F. Nixon, MD, PhDk
Abstract: Association of HIV-1–specific T-cell responses to
infection risk in seronegative individuals is controversial. We
quantified and phenotypically characterized gp120-specific T-cell
responses in HIV-1 exposed, but uninfected subjects enrolled in the
global Pre-exposure Prophylaxis Initiative (iPrEx) chemoprophylaxis
trial. IFNg ELISpot responses were detected in 24% of subjects
irrespective of infection outcome. HIV-1 gp120 envelope-specific
T-cell responses were more uniformly IFN-g+TNF-a+Mip-1b+ in
persistently seronegative subjects relative to subjects who later
seroconverted (median frequency of 76.5% and 66.5%, respectively).
IFNg responses targeted the V2 loop for subjects who remained
seronegative. HIV-1 gp120 envelope V2 loop-specific CD8+ T-cell
responses may help to protect against HIV-1 acquisition.
Key Words: HESN, polyfunctionality, T cell, CD8+, vaccine
(J Acquir Immune Defic Syndr 2016;72:184–188)
INTRODUCTION
The RV144 immune correlates analysis was an impor-
tant achievement, establishing the framework on which future
prophylactic HIV-1 vaccines are being developed. The
analysis showed that a humoral immune response of the right
immunoglobulin class to the V1V2 region of gp120 was
associated with vaccine efficacy.1 The vaccine regimen
induced T-cell responses, in particular CD4+ polyfunctional
T cells,2 but this was not associated with infection outcomes
in the analysis of primary variables despite suggestions of an
association among secondary variables.1
The association of T-cell responses and reduced infection
risk is controversial. Inducing T cells using an adenovirus-
vectored Gag/Pol/Nef vaccine failed to protect human vaccines
from HIV-1 infection and may have increased infection risk.3,4
In contrast, results from cytomegalovirus-vectored simian
immunodeficiency virus vaccination of nonhuman primates
showed vaccine-elicited CD8+ T cells, which associated with
viral suppression.5 We have also recently shown a reduced
infection risk associated with naturally acquired T-cell re-
sponses in the iPrEx trial.6
More recently, a reanalysis of the RV144 T-cell
response data suggested that HIV-1 gp120 envelope-specific
T-cell responses are part of the protective immune response in
vaccines. This reanalysis used the novel, open source
analytical tool COMPASS, enabling a more thorough dissec-
tion of the complexities of T-cell polyfunctionality and
overall response in RV144. The results indicated that the
CD4+ T-cell responses had protective associations that were
comparable in magnitude with the previously reported
humoral responses.7 The totality of the RV144 data indicated
that vaccine-induced HIV-1 prophylactic efficacy is linked to
both humoral and cellular immunity and that the qualitative
characteristics are critical in determining outcomes. The
results also suggested that a response against a single protein
antigen, with the optimal qualitative characteristics, may be
sufficient for protection.
The RV144 analyses were constrained to immune
responses mechanistically related to the vaccination and
study-related variables and thus not designed to address other
mechanisms of reduced HIV-1 infection risk. One mechanism
of potential-reduced infection risk, vaccine-induced HIV-1–
specific CD8+ T-cell responses, could not be rigorously tested
in the correlates analysis because of the low frequency,
consistent with the vaccine’s design. We have shown that
HIV-1–specific T-cell responses are present in some HIV-1–
exposed seronegative (HESN) subjects and that certain
responses were associated with reduced HIV-1 infection
risk.6 In that initial study, responses to the gp120 protein
antigen were not assessed.
In light of the RV144 results and evidence of protective
naturally acquired T-cell immunity, it may also be possible
that CD8+ gp120-specific T-cell responses could contribute to
protection. In support of this are reports of naturally induced
T-cell responses specific for gp120 described in cohorts of
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HIV-1 exposed but persistently seronegative individuals, both
from sexual and occupational HIV-1 exposure.8–11 We
hypothesized that gp120-specific CD8+ T-cell responses,
quantitatively or qualitatively, would be associated with
infection risk among comparably exposed placebo-treated
individuals in the global Pre-exposure Prophylaxis Initiative
(iPrEx) chemoprophylaxis trial.12
METHODS
Our study was designed as a case–control cross-
sectional analysis of gp120-specific IFNg cellular immune
responses with phenotypic characterization of positive re-
sponses. We examined gp120-specific cellular immune
responses from preinfection-cryopreserved peripheral blood
mononuclear cells (PBMCs) from 25 subjects who serocon-
verted during the follow-up period of the iPrEx trial (median
time-on-study at the time of documented infection was 561
days for this group). The most proximal HIV-1–negative time
point relative to diagnosis of HIV-1 infection was used for the
analyses with HIV-1–negative status at this time point
determined by a combination of HIV-1 antibody and HIV-1
RNA testing. These subjects were designated seroconverters–
before infection (SC-BI). Each SC-BI was matched to 3
persistently HIV-1–negative trial participants (HESN; n = 75)
from the same enrollment site with comparable time-on-study
as the SC-BI participant (n = 75). All PBMC specimens used
in the study were obtained from consented participants of the
iPrEx trial completed in 2010 (registered with ClinicalTrials.
gov, NCT00458393). All subjects were randomized to
placebo in the trial.
We used a prespecified 2-step process first screening
with an IFN-g ELISpot assay followed by phenotypic
characterization and response confirmation with multipara-
metric flow cytometry (MFC) where PBMCs were available
from the same aliquot.
IFN-g ELISpot assays were conducted with peptide
pools consisting of 15-mer peptides overlapping by 11 amino
acids (AA) from NIH AIDS Research and Reagent Program
(Rockville, MD) that spanned gp120 protein antigen with
sequences corresponding to HIV-1 consensus B sequence. A
gp120 pool and series of matrix peptide pools along with
individual peptide preparations were used in the experiment.
All peptides were reconstituted, pooled, and used at a final
concentration of 5 mg/mL. PBMCs were plated at a concen-
tration of 1 · 105 cells/well and incubated overnight (16–18
hours). Two positive controls (phytohaemagglutinin, and
a peptide pool consisting of cytomegalovirus, Epstein Barr
virus, and influenza virus peptides) were also included. No
reassays were permitted and all data included in the analyses
to ensure objectivity. A positive gp120 response in ELISpot
was defined as $55 spots per million PBMCs after subtract-
ing twice the spot count in the negative control well.
MFC was performed on the same PBMC aliquot from
which ELISpot responses were detected and within 1 day of
thawing. All runs included an unstimulated negative control
condition. Costimulatory anti-CD28 and CD49d mAbs were
added for every 1 · 106 cells in all conditions. Peptides were
added at 5 mg/mL incubated for 1 hour at 37°C after which 50
mL of Brefeldin A was added then incubated over night. Cells
were stained in the presence of human IgG (Sigma) with
Pacific Blue anti-CD3 (BioLegend), Brilliant Violet 605
anti-CD8 (BioLegend), Brilliant Violet 650 anti-CD4
(BioLegend), and allophycocyanin/cyanine 7 anti-CD14 and
anti-CD19 (Biolegend). Amine Aqua (Life technologies) was
included in each stain to exclude dead cells. The cells were
fixed, washed, pelleted, and permeated. Cells were then
stained intracytoplasmically with allophycocyanin anti-IFNg
(BD Pharmingen), TNF-a with Alexa Fluor (BD Pharmin-
gen), and Mip-1b with PE-A (BD Pharmingen). Cells were
washed, pelleted, and fixed a final time. Samples were
analyzed on a 4-laser LSR II flow cytometer (BD Bioscien-
ces, San Jose). Data analysis was performed using FlowJo
Version 9.6.1 software (TreeStar, Ashland, OR). A minimum
number of 50 events were required before the population
could be considered.
RESULTS
All subjects mounted IFN-g responses to either the
positive peptide pool or phytohaemagglutinin control; no
statistically significant differences were noted between SC-BI
and HESN. The frequency of positive gp120-specific re-
sponses was equal between groups at 24%. Median (inter-
quartile range) spots per million counts for SC-BI and HESN
were 775 (188–995) and 160 (106–569), respectively (Fig.
1A). The difference in magnitude of response for SC-BI and
HESN did not meet statistical significance.
FIGURE 1. ELISpot and poly-
functionality. A, ELISpot results. Of
the 25 SC-BI tested, 6 (24%) had
counts above the 55 spot per million
threshold (indicated by the dotted
line) with a median [interquartile
range (IQR)] of 775 (188–995). An
equal frequency (24%) of HESN, or
18/74, had counts above the
threshold with a median (IQR) of
160 (106–569). B, Multiparametric
flow cytometry. Median (IQR) per-
cent of IFNg+TNFa+Mip-1b+ T cells
of 76.5 (69.8–84.4) in 9 HESN and
66.5 (51.5–89.8) in 5 SC-BI.
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IFN-g responses to the gp120 peptide pool were
confirmed by MFC in each of the 5 SC-BIs and 9 HESNs
who had a positive T-cell response in ELISpot and sufficient
PBMC to conduct the testing (Fig. 1B). Figure 2A shows
a representative SC-BI and HESN gp120 response. Non-
specific IFN-g responses were low after incubation with cell
culture medium alone in the presence of costimulation.
Responses were CD8+ T cell polarized in all cases tested
with a trend of stronger responses in HESN when tested in
MFC. Responses were detected on subsequent visits indicat-
ing persistence of responses in those tested (Fig. 2B). T-cell
responses were more uniformly polyfunctional as measured
by TNF-a and Mip-1-b coproduction in HESN in comparison
with SC-BI with a median (interquartile range) frequency of
76.5 (69.8–84.4) and 66.5 (51.5–89.8), respectively (Fig. 1B).
Insufficient numbers of subjects were studied to enable
rigorous statistical comparisons of polyfunctionality.
We mapped epitope-specific responses in 1 SC-BI and
1 HESN from the same enrollment site, both at Day 144 of
follow-up. We determined that the HESN subject reacted to at
least 2 epitopes. One epitope comprised AA102–116 (based
on the HXB2 sequence) lying proximal to the CD4 binding
site and V1 loop region (Fig. 2C). The other epitope was
located within the V2 loop region comprising HXB2 AA178-
192, containing a glycosylation site at AA186-188. In
contrast, the SC-BI subject demonstrated a weak reactivity
to 2 overlapping 15-mer peptides on the gp120 pool. Both
peptides spanned AA213-231, outside the V1V2 loop. The
weaker response was against the peptide with a partial
overlapping of an NKT glycosylation site (Fig. 2C). A second
HESN from another enrollment site responded to a V2 loop
epitope, HXB2 AA171-185 (Fig. 2C), proximal to the
AA186-188 glycosylation site.
DISCUSSION
The importance of gp120 responses (both humoral and
cellular) in the protection from a productive systemic
infection with HIV-1 has been established. In the RV144
trial, T-cell responses in vaccines were CD4+, targeted the V2
loop, and were associated with a predominance of IL2 or IFN-
g production, or a polyfunctional combination of the 2 in
vaccinated subjects.2 The COMPASS analysis shed further
light on the qualitative characteristics strongly suggesting
a CD4+ T-cell response to be contributing to reduced
infection risk. A corroborating study in rhesus monkeys also
showed the importance of gp120 responses to protection.13
These studies were not designed to assess other potentially
protective immune responses.
Leveraging the placebo-controlled iPrEx trial with its 3-
year follow-up period together with limiting our analysis to
subjects receiving placebo only provided a naturalistic setting
in which to investigate risk-associated gp120 T-cell re-
sponses. This unique approach enabled an assessment of
HIV-1–specific immunity that was not biased by vaccination
or pharmacologic interventions. In our study, we confirmed
that HIV-1 gp120-specific IFN-g responses were present in
both SC-BI and HESN. The prevalence did not differ between
the groups but the medians suggested a 4.8-fold greater
response magnitude in SC-BI. Such results corroborate the
potential of T-cell responses to increase infection risk.3
However, the qualitative characteristics of the responses
differentiated with infection outcomes similar to the
COMPASS analysis and affirming the importance of quali-
tative factors of immune response in the overall impact of an
immune response.
We observed a more homogenously polyfunctional
response in HESN with a greater frequency of Mip-1b+ cells
in HESN. This observation is analogous to the dominance of
CD4+ T-cell polyfunctionality observed in RV144 vaccines,2
although the range of detected cytokines differed between the
2 studies. Our result also mirrors analyses conducted in HIV-
1 vaccines immunized with a DNA prime/rAd5 boost that
showed that CD8+ polyfunctionality, inclusive of Mip-1b and
CD107a, was correlated to antiviral activity.14 Although our
subject numbers were limited, which impacted our ability to
conduct rigorous statistical testing and may have obscured the
contribution of CD4+ T-cell responses in the larger popula-
tion, the overall trend suggests that a more uniformly
polyfunctional T-cell response may be associated with the
relative resistance to HIV-1 infection.
The most impressive corroborative link between our
study and the RV144 analyses is the overlap of targeted
epitopes. In RV144, responses were predominantly directed
to the V2 loop region and specifically HXB2 AA172-204
containing the a4b7-binding motif and glycosylation sites at
AA186-188 and AA197-199.2 In the mapped iPrEx partic-
ipants, we observed similar regional targeting for 2 HESN but
not the SC-BI. Importantly, one of the HESN came from the
same enrollment site and the PBMC samples from the same
protocol-defined visit as the SC-BI. However, the overlap
with the findings in the RV144 analyses suggests that gp120
V2 loop-specific CD8+ specific T-cell responses together with
humoral and CD4+ T-cell immune responses may be
important for protection from HIV-1 infection.
We show that qualitative characteristics of gp120-
specific CD8+ T-cell responses differentiate with infection
outcomes. The study was principally designed to assess
ELISpot IFN-g responses and to phenotypically characterize
those that were positive. Thus, the number of studied
responses overall and peptide-mapped responses in particular
were small, and the range of cytokines was less expansive
relative to those of previous studies.1,2,6,7 In addition, 15-mer
peptides are used for detection of both class-I and class-II T-
cell responses so the absence of CD4+ T-cell responses is
likely stochastic. The study was also not designed to assess
protection; therefore, the gp120-specific responses could be
a marker of exposure and not related to mechanisms of
resistance. However, the striking overlap between the obser-
vations in this study, particularly in a case–control pairing, to
that of others linked with vaccine efficacy may suggest that
polyfunctional CD4+ and CD8+ gp120-specifc T-cell re-
sponses could enhance the protective effect of a prophylactic
HIV-1 vaccine. Therefore, a larger study of naturalistic
exposure to HIV-1 with additional polyfunctionality variables
is needed to make robust conclusions.
In conclusion, we observed strong, polyfunctional
CD8+ T-cell responses specific for the V2 loop of HIV-1
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FIGURE 2. Confirmation of ELISpot responses $55 spots per million (SPM) with multiparametric flow cytometry. Cryopreserved
PBMCs were tested first in and IFN-g ELISpot assay with gp120 responses confirmed in MFC. HESNs or SC-BIs shown are individual
subjects; flow data in this figure for each HESN or SC-BI were used once. A, Example of SC-BI and HESN responses in the absence of
stimulating peptide pools and in the presence of gp120 peptide pool at 5 mg/mL, proportion of CD4+ and CD8+ IFN-g–positive cells,
and proportion of CD8+ IFN-g–positive cells also positive for TNF-a and Mip-1b (CD4+ IFN-g–positive T-cell frequency was too low to
examine for polyfunctionality). B, Time dependency of response to gp120 peptide pool in a HESN, tested at 5 mg/mL. C1, 15-mer
peptide mapping of positive gp120 response from a matrix ELISpot. The HESN individual demonstrated 2 distinct positive responses,
and the SC-BI individual from the same enrollment site at the same protocol-defined visit had 2 positive responses to overlapping 15-
mer peptides. C2, peptide mapping in an additional HESN. The amino acid sequence and positions are from HXB2.
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gp120 in HIV-1 exposed but persistently seronegative
individuals. In the subjects tested, the qualities and regional
epitope specificity differed in persistently negative HESN
individuals relative to those individuals who eventually
became infected. The observations made in this study
corroborate the ground-breaking analyses and observations
of the envelope-based RV144 vaccine study regarding CD4+
T-cell polyfunctionality. The concordance of the findings
suggests that CD8+ T-cell responses may also contribute to
protection from infection and should be further studied in
sufficiently powered studies, inclusive of prospectively
designed retrospective studies of vaccine, and pre-exposure
prophylaxis trials.
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